New radiotherapy treatment promises better cure rates with fewer side effects

Video: A SABR radiotherapy session in real time.

The SABR Prostate Trial

PCF and our partners are funding a national clinical trial to demonstrate the benefits of Stereotactic Ablative Body Radiotherapy (SABR).

The  trial, which is taking place at nine Canadian cancer centres (and is part of a large-scale international trial called PACE), comes after early research indicated that SABR may deliver better cure rates with fewer side effects than the standard radiotherapy protocol.

With SABR, radiation sessions are reduced from 39 to just five. 

---

“SABR has the potential to become the new standard of care for favourable-risk prostate cancer patients,” ​said Dr. Andrew Loblaw, Founder and Chair of the Prostate Cure Foundation, Clinician Scientist and GU site Group Lead, Department of Radiation Oncology at Sunnybrook Health Sciences Centre. 

---

Here are just a few of the benefits being tested in this trial:

Reduced Side Effects in Sexual and Urinary Functioning ​

96% of SABR patients retain normal sexual function compared to baseline. 

Read the Study

High Rates of Remission Five Years After Treatment 

99% for low-risk patients and 93% for intermediate-risk patients. 

Read the study

Lower Treatment Cost Per Patient 

Cost for 5-session SABR is $1,470 vs. $6,987 for 39-session EBRT.

Read the study

Download the SABR
​Prostate Trial Infographic

Read about all the SABR benefits demonstrated in preliminary research.

Download

---

How to get the SABR treatment​

The SABR Prostate Trial completed its accrual on December 31, 2017. We are no longer looking for men to participate in the study. 

If you think you might benefit from SABR, please contact your oncologist. Currently, Sunnybrook Health Sciences Centre in Toronto is offering SABR to patients who qualify for the treatment. 

We anticipate that the cancer centres that were trained to participate in the SABR Trial may offer the treatment in the near future. We will post updates as they become available

Participating Cancer Centres

---

Thank you to our partners for making the SABR Trial possible!

Co-sponsor

Partners